A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Aichi
-
Nagoya-shi, Aichi, Japan
-
-
Akita
-
Akita-shi, Akita, Japan
-
-
Aomori
-
Aomori-shi, Aomori, Japan
-
-
Chiba
-
Chiba-shi, Chiba, Japan
-
-
Ehime
-
Touon-shi, Ehime, Japan
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan
-
Kitakyusyu-shi, Fukuoka, Japan
-
-
Fukushima
-
Fukushima-shi, Fukushima, Japan
-
-
Gunma
-
Maebashi-shi, Gunma, Japan
-
-
Hiroshima
-
Higashihiroshima-shi, Hiroshima, Japan
-
Miyoshi-shi, Hiroshima, Japan
-
Otake-shi, Hiroshima, Japan
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japan
-
-
Iwate
-
Ichinoseki-shi, Iwate, Japan
-
-
Kanagawa
-
Sagamihara-shi, Kanagawa, Japan
-
Yokohama-shi, Kanagawa, Japan
-
-
Kochi
-
Nangoku-shi, Kochi, Japan
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan
-
-
Mie
-
Tsu-shi, Mie, Japan
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan
-
Watari-gun, Miyagi, Japan
-
-
Nagano
-
Nagano-shi, Nagano, Japan
-
-
Nagasaki
-
Higashisonogi-gun, Nagasaki, Japan
-
-
Niigata
-
Kashiwazaki-shi, Niigata, Japan
-
Niigata-shi, Niigata, Japan
-
-
Okayama
-
Tsukubo-gun, Okayama, Japan
-
-
Okinawa
-
Ginowan-shi, Okinawa, Japan
-
-
Osaka
-
Toyonaka-shi, Osaka, Japan
-
-
Saitama
-
Hasuda-shi, Saitama, Japan
-
Saitama-shi, Saitama, Japan
-
-
Shiga
-
Otsu-shi, Shiga, Japan
-
-
Shizuoka
-
Hamamatsu-shi, Shizuoka, Japan
-
Shizuoka-shi, Shizuoka, Japan
-
-
Tochigi
-
Shimotsuke-shi, Tochigi, Japan
-
-
Tokushima
-
Tokushima-shi, Tokushima, Japan
-
Yoshinogawa-shi, Tokushima, Japan
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan
-
Kodaira-shi, Tokyo, Japan
-
Ota-ku, Tokyo, Japan
-
-
Wakayama
-
Wakayama-shi, Wakayama, Japan
-
-
Yamagata
-
Yonezawa-shi, Yamagata, Japan
-
-
Yamaguchi
-
Shimonoseki-shi, Yamaguchi, Japan
-
Yanai-shi, Yamaguchi, Japan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who are able to submit written informed consent. If patients are duly capable of study consent but are unable to sign (or affix a seal) by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.
- Patients who are aged 20 years or older at the time of obtaining informed consent.
- Patients who have clinically definite ALS, clinically probable ALS, or clinically probable-laboratory supported ALS as specified in the revised El Escorial Airlie House diagnostic criteria.
- Patients who are at stage 1 or 2 of the severity criteria for ALS.
- Patients within 3-year elapsed time period from disease onset at the start of observation period.
- Patients who can visit study site for out-patient treatment.
Exclusion Criteria:
- Patients who underwent tracheostomy.
- Patients who experienced non-invasive positive pressure ventilation.
- Patients whose percent-predicted forced vital capacity (%FVC) is >=60%.
- Patients with multiple disturbances of conduction detected by nerve conduction test.
- Patients with neurological symptom(s) due to vitamin B12 deficiency.
- Patients who initiated newly introduced riluzole therapy after starting the observation period. Or those who received dose escalation or resumed administration of riluzole therapy after previous down titration or discontinuation.
- Patients with cognitive impairment.
- Pregnant women or women with a possibility of becoming pregnant.
- Patients or their partners who are not willing to use reliable contraception.
- Patients with severe disease in the renal, cardiovascular, hematological, or hepatic system (severe disease will be judged referring to "Ministry of Health, Labor and Welfare" (MHLW) Drug Safety Dept. Notification No. 80, Drug Safety Classification Criteria for Severity of Adverse Drug Reaction by Medicinal Products, Grade 3).
- Patients with malignant tumor.
- Patients who participated in another clinical study within 12 weeks before starting the observation period.
- Patients with present illness or history of drug allergy or severe allergic disease (anaphylactic shock).
- Patients who are judged to be ineligible for study entry by the investigator or subinvestigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: 3
|
Intramuscular injection, placebo twice a week for 3.5 years.
|
|
Experimental: E0302 25 mg
|
Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
Other Names:
Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
Other Names:
|
|
Experimental: E0302 50 mg
|
Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
Other Names:
Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Survival rate
Time Frame: Every 3 months.
|
Every 3 months.
|
|
Functional rating scale.
Time Frame: Every 3 months.
|
Every 3 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Manual Muscle Test (MMT)
Time Frame: Every 3 months.
|
Every 3 months.
|
|
Percent-predicted forced vital capacity (%FVC)
Time Frame: Every 3 months.
|
Every 3 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Kazunori Saeki, Neuroscience Clinical Development Section. JAC PCU. Eisai Co., Ltd.
Publications and helpful links
General Publications
- Kaji R, Imai T, Iwasaki Y, Okamoto K, Nakagawa M, Ohashi Y, Takase T, Hanada T, Shimizu H, Tashiro K, Kuzuhara S. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):451-457. doi: 10.1136/jnnp-2018-319294. Epub 2019 Jan 13.
- Ikeda K, Iwasaki Y, Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2015 Jul 15;354(1-2):70-4. doi: 10.1016/j.jns.2015.04.052. Epub 2015 May 8.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Sclerosis
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Vitamin B Complex
- Vitamin B 12
Other Study ID Numbers
Other Study ID Numbers
- E0302-J081-761
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.